A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Summary

Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also assess safety, pharmacokinetics (PK) and changes in liver fat content related to patients diagnosed with MASH.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• MASH - Metabolic Dysfunction-Associated Steatohepatitis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

30 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Rivus Pharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

May 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites